Pharmacogenomics: Ethical and regulatory issues

In Bonnie Steinbock (ed.), The Oxford Handbook of Bioethics. Oxford University Press (2009)
  Copy   BIBTEX


While acknowledging the potential benefits of pharmacogenomics as a methodology, a number of comprehensive reports in the past several years examine a multitude of ethical, legal, and social factors that may limit the extent to which these benefits are realized — and realized in ethically acceptable ways. This article aims to identify and explore the most basic ethical and regulatory issues that are likely to arise if pharmacogenomics becomes widely enough used to have a significant impact on research and clinical practice. First, however, it addresses the question of whether pharmacogenomic tests are unique when compared to other genetic tests and thus deserving of more or less stringent ethical and regulatory requirements.



    Upload a copy of this work     Papers currently archived: 89,654

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Pharmacogenomics, ethics, and public policy.Karen Peterson-Iyer - 2008 - Kennedy Institute of Ethics Journal 18 (1):pp. 35-56.
Ontological Issues in Pharmacogenomics.Russ B. Altman - 2007 - The Monist 90 (4):523-533.
Pharmacogenomics: Social, Ethical, and Clinical Dimensions.A. Hedgecoe - 2004 - Journal of Medical Ethics 30 (6):e6-e6.
Innovative surgery: the ethical challenges.Jane Johnson & Wendy Rogers - 2012 - Journal of Medical Ethics 38 (1):9-12.
The Troubling Persistence of Race in Pharmacogenomics.Jonathan Kahn - 2012 - Journal of Law, Medicine and Ethics 40 (4):873-885.


Added to PP

31 (#439,647)

6 months
2 (#649,073)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Allen Buchanan
University of Arizona

References found in this work

No references found.

Add more references